N-ethyl-(2R,5S)-2,5-dimethylpiperazine | 1072102-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-ethyl-(2R,5S)-2,5-dimethylpiperazine
• 英文别名: (2R,5S)-rel-1-Ethyl-2,5-dimethylpiperazine；(2R,5S)-1-ethyl-2,5-dimethylpiperazine
• CAS: 1072102-27-2
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: QNTATFFRXJXEKI-JGVFFNPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 5-(chlorocarbonyl)-3-[(ethoxycarbonyl)amino]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate 、 N-ethyl-(2R,5S)-2,5-dimethylpiperazine 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 ethyl 3-[(ethoxycarbonyl)amino]-6,6-dimethyl-5-{[4-ethyl-(2S,5R)-2,5-dimethylpiperazin-1-yl]carbonyl}-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate
  参考文献：
  名称：

  WO2008/125945

  摘要：

  公开号：

文献信息

• Acylated piperidine derivatives as melanocortin-4 receptor modulators
  申请人：Bakshi Raman K.

  公开号：US20090253744A1

  公开（公告）日：2009-10-08

  Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

  某些新型N-酰化的螺环吡啶衍生物是人类黑色素细胞素受体的配体，特别是人类黑色素细胞素-4受体（MC-4R）的选择性配体。因此，它们可用于治疗、控制或预防对MC-4R调节敏感的疾病和障碍，如肥胖症、糖尿病、尼古丁成瘾、酗酒、性功能障碍，包括勃起功能障碍和女性性功能障碍。
• NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES
  申请人：Botrous Iriny

  公开号：US20100249128A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

  本发明涉及式（I）的化合物和药学上可接受的盐，其中X，R1，R2，R3，R4，R5，R6，R7和R8如上所定义。本发明还涉及包含该化合物和药学上可接受的盐的制药组合物以及治疗糖尿病及其并发症（尤其是糖尿病视网膜病变、肾病或神经病变）、癌症、缺血、炎症、中枢神经系统疾病、心血管疾病、阿尔茨海默病和皮肤病、病毒性疾病、炎症性疾病或肝脏是靶器官的疾病的治疗方法。
• NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES
  申请人：Botrous Iriny

  公开号：US20120108588A1

  公开（公告）日：2012-05-03

  The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

  本发明涉及公式（I）的化合物和药学上可接受的盐，其中X，R1，R2，R3，R4，R5，R6，R7和R8如上所定义。本发明还涉及包含该化合物和药学上可接受的盐的制药组合物，以及治疗糖尿病及其并发症（尤其是糖尿病视网膜病变，肾病或神经病变），癌症，缺血，炎症，中枢神经系统疾病，心血管疾病，阿尔茨海默病和皮肤病，病毒性疾病，炎症性疾病或肝脏是靶器官的疾病的治疗方法。
• US8114871B2
  申请人：——

  公开号：US8114871B2

  公开（公告）日：2012-02-14
• US8999981B2
  申请人：——

  公开号：US8999981B2

  公开（公告）日：2015-04-07